| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.
|
J Clin Oncol
|
2005
|
7.12
|
|
2
|
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.
|
J Clin Oncol
|
2004
|
3.40
|
|
3
|
Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.
|
Invest New Drugs
|
2007
|
1.18
|
|
4
|
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.
|
Eur J Cancer
|
2010
|
1.09
|
|
5
|
A Culturally Targeted Website for Hispanics/Latinos About Living Kidney Donation and Transplantation: A Randomized Controlled Trial of Increased Knowledge.
|
Transplantation
|
2016
|
0.83
|
|
6
|
Analysis of survival in 400 surgically resected non-small cell lung carcinomas: towards a redefinition of the T factor.
|
J Thorac Oncol
|
2008
|
0.78
|
|
7
|
Effect of a Mobile Web App on Kidney Transplant Candidates' Knowledge About Increased Risk Donor Kidneys: A Randomized Controlled Trial.
|
Transplantation
|
2016
|
0.75
|